HOME >> MEDICINE >> NEWS
Promising drug fails to improve COPD symptoms

NF-, and a number of studies have reported increased production of TNF in COPD patients. This increased production has been linked to weight loss, muscle weakness and muscle loss.

In addition, animal studies supported the prospect using the drug in COPD. When TNF- was infused into rats, they developed emphysema, which, along with chronic bronchitis, makes up most COPD cases. When the TNF- receptor was turned off in mice, they were less likely than mice that had not be genetically altered to develop emphysema when exposed to chronic cigarette smoke.

The latest study, however, did confirm a recently reported pilot study that found no improvement among the 14 COPD patients given infliximab.

In attempting to explain the disappointing results, the study authors speculate that, despite infliximab's efficacy in treating other inflammatory diseases, it may not be effective in COPD because other mediators, in addition to TNF-, are necessary to cause COPD. They also concede that six months may simply be too short a time period to see improvement.

However, an increased number of malignancies observed in infliximab-treated subjects, the authors said, raised concern about the safety of this drug in lung patients. Although the malignancies may have been present when the patients enrolled in the study, "the possibility that infliximab contributed to the progession, and thus the diagnosis, of malignancies remains a serious concern."

This safety issue, coupled with the "resoundingly negative results," make in unlikely that a longer trial will be undertaken, according to the accompanying editorial.


'"/>

Contact: Suzy Martin
smartin@thoracic.org
212-315-8631
American Thoracic Society
1-May-2007


Page: 1 2

Related medicine news :

1. Promising therapy for ALS delivers antisense drug directly to nervous system
2. Promising new treatment for ulcerative colitis sufferers
3. Promising advance in breast cancer research
4. Promising obesity therapy receives follow-on funding
5. Promising diagnostic tools for multiple sclerosis developed at Yale
6. Promising therapies for haemophilia & heart disease
7. Promising new TB drug enters clinical trial
8. Promising new West Nile therapy cures disease in mice
9. Government fails sleepy Judge Dodd
10. Pairing medical therapy with coronary intervention fails to reduce heart disease deaths
11. Community and clinic-based HIV-1 control program fails to decrease incidence of HIV-1 in Zimbabwe

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Promising drug fails improve COPD symptoms

(Date:4/21/2015)... The report “Dermatitis – ... on the therapeutic development for Dermatitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Dermatitis ...
(Date:4/21/2015)... Edward Avalos, USDA Under Secretary for Marketing and ... the California Department of Food and Agriculture, have been ... Conference: The Future of Local Food, conference organizers announced ... known experts intensifies an already strong line-up of sustainable ... to speak at the June 11-13 event. ...
(Date:4/21/2015)... Wojo Nutrition announces Abe’s ... its healthiest, will carry Wojo Nutrition's lines of single ... Nutrition, they’ve launched a revolution in the vitamin industry ... meet their multifaceted goals. Their line of single serving ... has been specially formulated to be as unique as ...
(Date:4/21/2015)... has released a new blog post explaining the ... , Comprehensive auto insurance is a complex policy ... limit can also be high and the premiums are ... against fire damage, vandalism, theft and from many other ... and it can help drivers find the right type ...
(Date:4/21/2015)... Health Advocate™, Inc., the nation’s leading ... West Corporation, is hosting a complimentary webinar on April ... benefits of offering this service to employees. , As ... their healthcare, it is critical that they have access ... their health benefits. Health advocates can play a significant ...
Breaking Medicine News(10 mins):Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Wojo Nutrition Announces their Lines of Single Serving Liquid Vitamins will be Available for Purchase online at Abesmarket.com Beginning in May 2Health News:Comprehensive Auto Insurance Is An Important But Complex Policy 2Health News:Health Advocate Webinar Discusses Benefits of Health Advocacy 2
(Date:4/21/2015)... SPRING, Md. , April 21, 2015 /PRNewswire-USNewswire/ ... told the U.S. Food and Drug Administration that ... worked effectively for the last 25 years to ... to safe homeopathic medicines. AAHP, the industry,s trade ... and consumers of homeopathic medicines to engage in ...
(Date:4/21/2015)... 21, 2015 Delcath Systems, Inc. (NASDAQ: ... Trial Authorizations (CTAs) filed with the U.K.,s ... and Germany,s Federal Institute for ... the Company,s global Phase 2 program for the treatment ... or HCC), to include a cohort of patients with ...
(Date:4/21/2015)... , April 21, 2015   Mast ... biopharmaceutical company leveraging its molecular adhesion and sealant ... sickle cell disease, heart failure, and arterial disease, ... EPIC study of its lead product ... surpassed the halfway point. Consistent with prior guidance, ...
Breaking Medicine Technology:Speakers at FDA Hearing Praise Success of Homeopathic Regulatory Framework 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 3Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 4Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 2Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 3Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 4Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 5
Cached News: